S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
NASDAQ:PRE

Prenetics Global (PRE) Stock Price, News & Analysis

$3.13
-0.06 (-1.88%)
(As of 12:06 PM ET)
Today's Range
$3.09
$3.22
50-Day Range
$3.15
$5.67
52-Week Range
$3.09
$15.90
Volume
21,004 shs
Average Volume
69,945 shs
Market Capitalization
$28.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Prenetics Global MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
187.5% Upside
$9.00 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

774th out of 918 stocks

Holding & Other Investment Offices Industry

8th out of 10 stocks

PRE stock logo

About Prenetics Global Stock (NASDAQ:PRE)

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

PRE Stock Price History

PRE Stock News Headlines

Prenetics Flat on Financial Results
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Prenetics Global: Q4 Earnings Insights
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Prenetics Global (PRE) Earnings Dates & Reports
PRENW Prenetics Global Limited WT EXP 051827
Prenetics Global Stock (NASDAQ:PRE) Insider Trades
Prenetics Global: Q3 Earnings Insights
Prenetics Announces Third Quarter 2023 Financial Results
Prenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?
Prenetics Global Ltd Class A PRE
Prenetics Global Limited Announces Reverse Stock Split
Prenetics Global Limited - Ordinary Shares - Class A
Prenetics Announces Second Quarter 2023 Financial Results
PRE - Prenetics Global Limited
See More Headlines
Receive PRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/15/2023
Today
4/19/2024
Next Earnings (Estimated)
6/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:PRE
Fax
N/A
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+187.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-62,720,000.00
Net Margins
-193.60%
Pretax Margin
-260.63%

Debt

Sales & Book Value

Annual Sales
$21.74 million
Book Value
$23.00 per share

Miscellaneous

Free Float
8,424,000
Market Cap
$28.61 million
Optionable
Not Optionable
Beta
-0.11
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Sheng Wu Yeung (Age 45)
    Co-Founder & CEO
  • Dr. Chi Hung Tzang Ph.D. (Age 49)
    Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. Hoi Chun Lo (Age 39)
    Chief Financial Officer
  • Dr. Yung Ho Wong DPHIL (Age 42)
    Chief Technology Officer
  • Ms. Yvonne L. Wong
    Chief Corporate Development Officer
  • Ms. Samantha Kwok
    Vice President People & Culture
  • Dr. Senthil Sundaram M.D. (Age 50)
    Chief Clinical Officer
  • Mr. Avrom Boris Lasarow (Age 47)
    Chief Executive Officer of EMEA
  • Dr. Shih-Chang Ong M.D. (Age 46)
    Chief Medical Officer & Member of Scientific Advisory Board
  • Mr. Joel Neoh
    Chief Consumer Officer & MD for CircleDNA

PRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Prenetics Global stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PRE shares.
View PRE analyst ratings
or view top-rated stocks.

What is Prenetics Global's stock price target for 2024?

1 brokers have issued 1 year target prices for Prenetics Global's shares. Their PRE share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 187.5% from the stock's current price.
View analysts price targets for PRE
or view top-rated stocks among Wall Street analysts.

How have PRE shares performed in 2024?

Prenetics Global's stock was trading at $5.91 at the start of the year. Since then, PRE stock has decreased by 47.0% and is now trading at $3.13.
View the best growth stocks for 2024 here
.

Are investors shorting Prenetics Global?

Prenetics Global saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,800 shares, an increase of 60.0% from the March 15th total of 8,000 shares. Based on an average daily volume of 69,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the company's shares are short sold.
View Prenetics Global's Short Interest
.

When is Prenetics Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024.
View our PRE earnings forecast
.

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) announced its quarterly earnings results on Friday, September, 15th. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.15. The company had revenue of $5.70 million for the quarter. Prenetics Global had a negative net margin of 193.60% and a negative trailing twelve-month return on equity of 11.15%.

When did Prenetics Global's stock split?

Shares of Prenetics Global reverse split on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners